RECRUITINGINTERVENTIONAL
Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program
Prevention of Chemotherapy-induced Peripheral Neuropathy With Therapeutic Exercise and Blood Flow Restriction Using PRESIONA Program
About This Trial
The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.
Who May Be Eligible (Plain English)
Who May Qualify:
- 18 years or older
- HER2+ breast cancer diagnosis
- On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)
Who Should NOT Join This Trial:
- Previous diagnosis of cancer
- Pregnant
- Cardiac pathology
- No symptoms or pathology that could be confused with neuropathy or related to diabetes
- No recommendation from oncologist for therapeutic exercise practice
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 18 years or older
* HER2+ breast cancer diagnosis
* On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)
Exclusion Criteria:
* Previous diagnosis of cancer
* Pregnant
* Cardiac pathology
* No symptoms or pathology that could be confused with neuropathy or related to diabetes
* No recommendation from oncologist for therapeutic exercise practice
Treatments Being Tested
OTHER
PRESIONA
Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
Locations (1)
University of Granada
Granada, Spain